• 1
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:13831389.
  • 2
    Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:13491357.
  • 3
    Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol. 2001;21:35.
  • 4
    Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:17121719.
  • 5
    Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15:467478.
  • 6
    Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003;75:S715S720.
  • 7
    Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:35423548.
  • 8
    Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med. 2006;34:660667.
  • 9
    Hoffmann G, Lutter G, Cremer J. Durability of bioprosthetic cardiac valves. Dtsch Arztebl Int. 2008;105:143148.
  • 10
    Antonini-Canterin F, Zuppiroli A, Popescu BA, et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol. 2003;92:14791482.
  • 11
    Farivar RS, Cohn LH. Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J Thorac Cardiovasc Surg. 2003;126:969975.
  • 12
    Antonini-Canterin F, Popescu BA, Zuppiroli A, et al. Are statins effective in preventing bioprosthetic aortic valve failure? A need for a prospective, randomized trial. Ital Heart J. 2004;5:8588.
  • 13
    Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:3447.
  • 14
    Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:11601164.
  • 15
    Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425430.
  • 16
    Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:22952322.
  • 17
    Chandrasekar B, Mummidi S, Mahimainathan L, et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem. 2006;281:1509915109.
  • 18
    Nakagami H, Jensen KS, Liao JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med. 2003;35:398403.
  • 19
    Yano M, Matsumura T, Senokuchi T, et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007;100:14421451.
  • 20
    Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335345.
  • 21
    Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:24422449.
  • 22
    Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:26102642.
  • 23
    Karimi A, Bidhendi LM, Rezvanfard M, et al. The effect of a high dose of atorvastatin on the occurrence of atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg. 2012;94:814.
  • 24
    Kourliouros A, De Souza A, Roberts N, et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg. 2008;85:15151520.
  • 25
    Kourliouros A, Roberts N, Jahangiri M. Statins with equivalent lipid-lowering capacity exhibit differential effects on atrial fibrillation after cardiac surgery. J Thorac Cardiovasc Surg. 2008;136:11001101; author reply 1101.
  • 26
    Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006;114:14551461.
  • 27
    Liakopoulos OJ, Kuhn EW, Slottosch I, et al. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev. 2012;4:CD008493.
  • 28
    Mithani S, Kuskowski M, Slinin Y, et al. Dose-dependent effect of statins on the incidence of acute kidney injury after cardiac surgery. Ann Thorac Surg. 2011;91:520525.
  • 29
    The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:24512496.
  • 30
    Butchart EG, Gohlke-Barwolf C, Antunes MJ, et al. Working Groups on Valvular Heart Disease, Thrombosis, and Cardiac Rehabilitation and Exercise Physiology, European Society of Cardiology. Recommendations for the management of patients after heart valve surgery. Eur Heart J. 2005;26:24632471
  • 31
    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
  • 32
    Allou N, Augustin P, Dufour G, et al. Preoperative statin treatment is associated with reduced postoperative mortality after isolated cardiac valve surgery in high-risk patients. J Cardiothorac Vasc Anesth. 2010;24:921926.
  • 33
    Angeloni E, Melina G, Benedetto U, et al. Statins improve outcome in isolated heart valve operations: a propensity score analysis of 3,217 patients. Ann Thorac Surg. 2011;92:6873.
  • 34
    Borger MA, Seeburger J, Walther T, et al. Effect of preoperative statin therapy on patients undergoing isolated and combined valvular heart surgery. Ann Thorac Surg. 2010;89:773779; discussion 779–780.
  • 35
    Clark LL, Ikonomidis JS, Crawford FA Jr, et al. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006;131:679685.
  • 36
    Fedoruk LM, Wang H, Conaway MR, et al. Statin therapy improves outcomes after valvular heart surgery. Ann Thorac Surg. 2008;85:15211525; discussion 5–6.
  • 37
    Folkeringa RJ, Tieleman RG, Maessen JG, et al. Statins Do not reduce atrial fibrillation after cardiac valvular surgery: a single centre observational study. Neth Heart J. 2011;19:1723.
  • 38
    Tabata M, Khalpey Z, Cohn LH, et al. Effect of preoperative statins in patients without coronary artery disease who undergo cardiac surgery. J Thorac Cardiovasc Surg. 2008;136:15101513.
  • 39
    Vaduganathan M, Stone NJ, Andrei AC, et al. Midterm benefits of preoperative statin therapy in patients undergoing isolated valve surgery. Ann Thorac Surg. 2012;93:18811887.
  • 40
    Virani SS, Nambi V, Lee VV, et al. Does preoperative statin therapy improve outcomes in patients undergoing isolated cardiac valve surgery? Am J Cardiol. 2008;102:12351239.
  • 41
    Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e652e735.
  • 42
    Nollert G, Miksch J, Kreuzer E, et al. Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement. J Thorac Cardiovasc Surg. 2003;126:965968.
  • 43
    David TE, Ivanov J. Is degenerative calcification of the native aortic valve similar to calcification of bioprosthetic heart valves? J Thorac Cardiovasc Surg. 2003;126:939941.
  • 44
    Le Tourneau T, Marechaux S, Vincentelli A, et al. Cardiovascular risk factors as predictors of early and late survival after bioprosthetic valve replacement for aortic stenosis. J Heart Valve Dis. 2007;16:483488.
  • 45
    Gring CN, Houghtaling P, Novaro GM, et al. Preoperative cholesterol levels do not predict explant for structural valve deterioration in patients undergoing bioprosthetic aortic valve replacement. J Heart Valve Dis. 2006;15:261268.
  • 46
    Kulik A, Masters RG, Bedard P, et al. Postoperative lipid-lowering therapy and bioprosthesis structural valve deterioration: justification for a randomised trial? Eur J Cardiothorac Surg. 2010;37:139144.
  • 47
    Antonini-Canterin F, Zuppiroli A, Baldessin F, et al. Is there a role of statins in the prevention of aortic biological prostheses degeneration. Cardiovasc Ultrasound. 2006;4:26.
  • 48
    Song YB, On YK, Kim JH, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J. 2008;156:373 e9e16.
  • 49
    Sakamoto H, Watanabe Y, Satou M. Do preoperative statins reduce atrial fibrillation after coronary artery bypass grafting? Ann Thorac Cardiovasc Surg. 2011;17:376382.
  • 50
    Aboyans V, Labrousse L, Lacroix P, et al. Predictive factors of stroke in patients undergoing coronary bypass grafting: statins are protective. Eur J Cardiothorac Surg. 2006;30:300304.
  • 51
    Pan W, Pintar T, Anton J, et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation. 2004;110:II45II49.
  • 52
    Koenig MA, Grega MA, Bailey MM, et al. Statin use and neurologic morbidity after coronary artery bypass grafting: A cohort study. Neurology. 2009;73:20992106.
  • 53
    Subramaniam K, Koch CG, Bashour A, et al. Preoperative statin intake and morbid events after isolated coronary artery bypass grafting. J Clin Anesth. 2008;20:411.
  • 54
    Gilmanov D, Bevilacqua S, Mazzone A, et al. Do statins slow the process of calcification of aortic tissue valves? Interact Cardiovasc Thorac Surg. 2010;11:297301.
  • 55
    Skowasch D, Schrempf S, Preusse CJ, Likungu JA, Welz A, Luderitz B, et al. Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins. Heart. 2006;92:495498.
  • 56
    Pineda A, Cubeddu LX. Statin rebound or withdrawal syndrome: does it exist? Curr Atheroscler Rep. 2011;13:2330.
  • 57
    Paraskevas KI, Mikhailidis DP. Statins may not prevent structural valve degeneration of aortic bioprosthetic valves, but should probably be prescribed to patients undergoing heart valve surgery nonetheless. Interact Cardiovasc Thorac Surg. 2010;11:302.
  • 58
    Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52C60C.
  • 59
    Hauer-Jensen M, Fort C, Mehta JL, et al. Influence of statins on postoperative wound complications after inguinal or ventral herniorrhaphy. Hernia. 2006;10:4852.